Skip to content

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Pfizer logo
PfizerPFE
1.8×+0.2×
Amgen logo
AmgenAMGN
20.6×-6.3×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
22.1×+11.8×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
+0.5×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
2.8×+2.2×

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.53B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's price / book?
Viking Therapeutics (VKTX) reported price / book of 7.5× in Q1 2026.
How has Viking Therapeutics's price / book changed year-over-year?
Viking Therapeutics's price / book increased by 134.1% year-over-year, from 3.2× to 7.5×.
What is the long-term trend for Viking Therapeutics's price / book?
Over 5 years (2020 to 2025), Viking Therapeutics's price / book has grown at a 28.1% compound annual growth rate (CAGR), from 1.8× to 6.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.